IL116249A - Nk-1 receptor antagonists for the treatment of neuronal damage and stroke - Google Patents

Nk-1 receptor antagonists for the treatment of neuronal damage and stroke

Info

Publication number: IL116249A
Authority: IL; Israel
Prior art keywords: stroke; derivatives; neuronal damage; receptor antagonists; epilepsy
Prior art date: 1994-12-12

Application number

IL11624995A

Other languages

English (en)

Other versions

IL116249A0 (en

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-12

Filing date

1995-12-04

Publication date

2003-07-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23394558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-12-04 Application filed by Pfizer filed Critical Pfizer

1996-03-31 Publication of IL116249A0 publication Critical patent/IL116249A0/xx

2003-07-06 Publication of IL116249A publication Critical patent/IL116249A/xx

Links

230000003961 neuronal insult Effects 0.000 title abstract 3
102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 2
108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 2
239000002464 receptor antagonist Substances 0.000 title abstract 2
229940044551 receptor antagonist Drugs 0.000 title abstract 2
208000006011 Stroke Diseases 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
206010015037 epilepsy Diseases 0.000 abstract 2
230000000302 ischemic effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
206010053648 Vascular occlusion Diseases 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
231100000318 excitotoxic Toxicity 0.000 abstract 1
230000003492 excitotoxic effect Effects 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
239000002742 neurokinin 1 receptor antagonist Substances 0.000 abstract 1
150000003053 piperidines Chemical class 0.000 abstract 1
150000003235 pyrrolidines Chemical class 0.000 abstract 1
150000008584 quinuclidines Chemical class 0.000 abstract 1
210000000278 spinal cord Anatomy 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1
208000021331 vascular occlusion disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pyrrole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)

IL11624995A 1994-12-12 1995-12-04 Nk-1 receptor antagonists for the treatment of neuronal damage and stroke IL116249A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US35470294A	1994-12-12	1994-12-12

Publications (2)

Publication Number	Publication Date
IL116249A0 IL116249A0 (en)	1996-03-31
IL116249A true IL116249A (en)	2003-07-06

Family

ID=23394558

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11624995A IL116249A (en)	1994-12-12	1995-12-04	Nk-1 receptor antagonists for the treatment of neuronal damage and stroke

Country Status (16)

Country	Link
US (1)	US6376507B1 (de)
EP (1)	EP0721778B1 (de)
JP (1)	JPH08239323A (de)
KR (1)	KR100195651B1 (de)
CN (1)	CN1132072A (de)
AT (1)	ATE260656T1 (de)
AU (1)	AU719159B2 (de)
CA (1)	CA2164804C (de)
DE (1)	DE69532625T2 (de)
DK (1)	DK0721778T3 (de)
ES (1)	ES2217274T3 (de)
IL (1)	IL116249A (de)
MY (1)	MY138631A (de)
NZ (1)	NZ280627A (de)
PT (1)	PT721778E (de)
ZA (1)	ZA9510483B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL116249A (en) *	1994-12-12	2003-07-06	Pfizer	Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
CO5011067A1 (es) *	1997-11-03	2001-02-28	Novartis Ag	Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen
AUPQ514600A0 (en) *	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
MXPA06013677A (es) *	2004-05-25	2007-02-13	Pfizer Prod Inc	Derivados de 3-amino-2-fenilpirrolidina.
GB0701365D0 (en) *	2007-01-24	2007-03-07	Glaxo Group Ltd	Novel pharmaceutical compositions
JP6334098B2 (ja) *	2013-06-24	2018-05-30	セイコーインスツル株式会社	表示機構、時計用ムーブメントおよび時計
US11040947B2 (en)	2017-03-22	2021-06-22	The Research Foundation For The State University Of New York	Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX18467A (es) *	1988-11-23	1993-07-01	Pfizer	Agentes terapeuticos de quinuclidinas
JPH072740B2 (ja) *	1990-06-01	1995-01-18	フアイザー・インコーポレイテツド	３―アミノ―２―アリールキヌクリジン
ATE116317T1 (de) *	1990-07-23	1995-01-15	Pfizer	Chinuclidinderivate.
EP0566589A1 (de) *	1991-01-10	1993-10-27	Pfizer Inc.	N-alkyl chinuclidiniumsalze als substanz-p-antagoniste
ES2065175T3 (es) *	1991-03-01	1995-02-01	Pfizer	Derivados de 1-azabiciclo(3.2.2)nonan-3-amina.
UA27776C2 (uk) *	1991-05-31	2000-10-16	Пфайзер Інк.	Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
CZ59394A3 (en) *	1991-09-26	1994-11-16	Pfizer	Condensed tricyclic heterocycles containing nitrogen as antagonists of p substance receptor, process of their preparation, intermediates, pharmaceutical preparations in which they are comprised and use
JP2656702B2 (ja) *	1992-03-23	1997-09-24	ファイザー製薬株式会社	ペプチド性キヌクリジン
ATE208376T1 (de) *	1992-08-19	2001-11-15	Pfizer	Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
AU7082194A (en) *	1993-09-17	1995-04-03	Pfizer Inc.	Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
DE69418046T2 (de) *	1994-11-16	1999-12-30	Bird S.A., Le Bourget Du Lac	Modularfahrradrahmen mit Vibrationsdämpfer
IL116249A (en) *	1994-12-12	2003-07-06	Pfizer	Nk-1 receptor antagonists for the treatment of neuronal damage and stroke

1995
- 1995-12-04 IL IL11624995A patent/IL116249A/xx not_active IP Right Cessation
- 1995-12-05 MY MYPI95003742A patent/MY138631A/en unknown
- 1995-12-07 DE DE69532625T patent/DE69532625T2/de not_active Revoked
- 1995-12-07 EP EP95308876A patent/EP0721778B1/de not_active Revoked
- 1995-12-07 DK DK95308876T patent/DK0721778T3/da active
- 1995-12-07 AT AT95308876T patent/ATE260656T1/de not_active IP Right Cessation
- 1995-12-07 ES ES95308876T patent/ES2217274T3/es not_active Expired - Lifetime
- 1995-12-07 PT PT95308876T patent/PT721778E/pt unknown
- 1995-12-08 CN CN95120596A patent/CN1132072A/zh active Pending
- 1995-12-08 AU AU40304/95A patent/AU719159B2/en not_active Ceased
- 1995-12-08 CA CA002164804A patent/CA2164804C/en not_active Expired - Fee Related
- 1995-12-08 NZ NZ280627A patent/NZ280627A/en unknown
- 1995-12-09 KR KR1019950048062A patent/KR100195651B1/ko not_active Expired - Fee Related
- 1995-12-11 ZA ZA9510483A patent/ZA9510483B/xx unknown
- 1995-12-12 JP JP7323355A patent/JPH08239323A/ja active Pending
1998
- 1998-06-18 US US09/099,289 patent/US6376507B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL116249A0 (en)	1996-03-31
PT721778E (pt)	2004-07-30
US6376507B1 (en)	2002-04-23
CN1132072A (zh)	1996-10-02
EP0721778A3 (de)	1999-11-10
NZ280627A (en)	2000-06-23
JPH08239323A (ja)	1996-09-17
MY138631A (en)	2009-07-31
AU719159B2 (en)	2000-05-04
DE69532625T2 (de)	2005-02-03
ATE260656T1 (de)	2004-03-15
CA2164804C (en)	1999-07-27
EP0721778A2 (de)	1996-07-17
ZA9510483B (en)	1997-06-09
CA2164804A1 (en)	1996-06-13
KR100195651B1 (ko)	1999-06-15
DE69532625D1 (de)	2004-04-08
DK0721778T3 (da)	2004-07-12
ES2217274T3 (es)	2004-11-01
KR960021025A (ko)	1996-07-18
EP0721778B1 (de)	2004-03-03
AU4030495A (en)	1996-06-20

Legal Events

Date	Code	Title
2004-01-04	FF	Patent granted
2004-02-08	KB20	Patent renewed for 20 years
2016-06-30	EXP	Patent expired

Publication	Publication Date	Title
EP0722737A4 (de)	1999-04-28	Arznei gegen die störung des cranialen nervan
EP0686629A3 (de)	1999-02-10	Cyclohexyl-Antagonisten von Tachykininrezeptoren
PL323871A1 (en)	1998-04-27	Compounds active at a new site on calcium passages controlled by a receptor, useful in treating neurological illnesses
IL114683A0 (en)	1995-11-27	Combination treatment for inhibiting bone loss
AU2606097A (en)	1997-11-12	Apparatus for treating movement disorders by closed loop brain stimulation
EP0703785A4 (de)	1998-12-30	Methoden zur behandlung von muskelerkrankungen und muskelstörungen
EG20218A (en)	1997-11-30	Process for preparing of substituted 3 aminoquinuclidines
BR0200283A (pt)	2002-10-08	Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
SE9303335L (sv)	1995-04-13	Ändsektion av rambalk
ATE302194T1 (de)	2005-09-15	Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
HU912359D0 (en)	1991-12-30	The use of flupirtine active agents for treating muscle-tension
IL116249A (en)	2003-07-06	Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
AU1463792A (en)	1992-10-06	N-substituted (alpha-imidazolyl-toluyl) pyrrole angiotensin ii antagonists for treatment of circulatory disorders
CA2143486A1 (en)	1995-09-02	Method of improving the immune response
ZA948928B (en)	1996-05-10	Melatonin derivatives for use in treating desynchronization disorders
CA2296560A1 (en)	1999-01-28	Amino acid derivatives useful to treat stroke
ZA948927B (en)	1996-05-10	Melatonin derivatives for use in treating sleep disorders
ATE161856T1 (de)	1998-01-15	Verfahren zum thermomechanischen abbau von polyolefinen
PL335802A1 (en)	2000-05-22	Method of treating vascular disorders
WO2002076437A3 (en)	2003-02-20	Methods for treating neurodegenerative diseases including alzheimer's
ZA982917B (en)	1999-10-06	Method for treating cerebral focal stroke.
BG105289A (en)	2001-11-30	The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2- (4-fluorophenyl)ethyl]-4-pip eridinemethanol for the treatment of sleep disorders
MX9709911A (es)	1998-03-31	Compuestos activos en un sitio novedoso en canales de calcio operados por receptor utiles para el tratamiento de trastornos neurologicos.
CA2257234A1 (en)	1997-12-11	Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
PL299147A1 (en)	1994-12-12	Pharmaceutical agent for treating central nerve system disorders